Cargando…

Urinary 6-sulfatoxymelatonin level in age-related macular degeneration patients

PURPOSE: Melatonin is a potent antioxidant and free radical scavenger. It has been reported that serum melatonin level is relevant to certain aging diseases. The purpose of this study was to investigate melatonin levels in age-related macular degeneration (AMD) patients by measurement of 6-sulfatoxy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rosen, Richard, Hu, Dan-Ning, Perez, Violete, Tai, Katy, Yu, Guo-Pei, Chen, Min, Tone, Paul, McCormick, Steven A., Walsh, Joseph
Formato:	Texto
Lenguaje:	English
Publicado:	Molecular Vision 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730752/ https://www.ncbi.nlm.nih.gov/pubmed/19710945

Ejemplares similares

Urinary 6-sulfatoxymelatonin level in girls and its relationship with obesity
por: Lee, Jieun, et al.
Publicado: (2012)

Intense solar activity reduces urinary 6-sulfatoxymelatonin in patients with COPD
por: Zilli Vieira, Carolina L., et al.
Publicado: (2023)

Urinary 6-sulfatoxymelatonin level and breast cancer risk: systematic review and meta-analysis
por: Xu, Jing, et al.
Publicado: (2017)

Lower nocturnal urinary 6-sulfatoxymelatonin is associated with more severe insulin resistance in patients with prediabetes
por: Reutrakul, Sirimon, et al.
Publicado: (2017)

Male-female differences in 6-sulfatoxymelatonin excretion in hypopituitary patients
por: Fideleff, Hugo L., et al.
Publicado: (2015)

Urinary Excretion of 6-Sulfatoxymelatonin, the Main Metabolite of Melatonin, and Mortality in Stable Outpatient Renal Transplant Recipients
por: van der Veen, Anna, et al.
Publicado: (2020)

Associations between urinary 6‐sulfatoxymelatonin excretion and diabetic vascular complications or arteriosclerosis in patients with type 2 diabetes
por: Tanaka, Kenichi, et al.
Publicado: (2020)

6-Sulfatoxymelatonin predicts treatment response to fluoxetine in major depressive disorder
por: Jury Freitas, Juliana, et al.
Publicado: (2019)

A cross-sectional analysis of light at night, neighborhood sociodemographics and urinary 6-sulfatoxymelatonin concentrations: implications for the conduct of health studies
por: Hurley, Susan, et al.
Publicado: (2013)

Circadian acclimatization of performance, sleep, and 6-sulfatoxymelatonin using multiple phase shifting stimuli
por: Youngstedt, Shawn D., et al.
Publicado: (2022)

The association of body size in early to mid-life with adult urinary 6-sulfatoxymelatonin levels among night shift health care workers
por: Ramin, Cody A, et al.
Publicado: (2015)

Sleep Problems and 6-Sulfatoxymelatonin as Possible Predictors of Symptom Severity, Adaptive and Maladaptive Behavior in Children with Autism Spectrum Disorder
por: Bartakovicova, Kristina, et al.
Publicado: (2022)

Optimisation of a Novel Bio-Substrate as a Treatment for Atrophic Age-Related Macular Degeneration
por: McCormick, Rachel, et al.
Publicado: (2020)

Urinary Mass Spectrometry Profiles in Age-Related Macular Degeneration
por: Lains, Ines, et al.
Publicado: (2022)

Effects of melatonin and its receptor antagonist on retinal pigment epithelial cells against hydrogen peroxide damage
por: Rosen, Richard B., et al.
Publicado: (2012)

The ERCC6 Gene and Age-Related Macular Degeneration
por: Baas, Dominique C., et al.
Publicado: (2010)

Subtoxic levels hydrogen peroxide-induced production of interleukin-6 by retinal pigment epithelial cells
por: Wu, Wen-Chuan, et al.
Publicado: (2010)

Macrophages and Macular Degeneration
por: Jager, Martine J.
Publicado: (2014)

Brolucizumab for macular degeneration
Publicado: (2020)

Age-related macular degeneration: current treatments
por: Hubschman, Jean Pierre, et al.
Publicado: (2009)

A Systematic Review of Carotenoids in the Management of Age-Related Macular Degeneration
por: Lem, Drake W., et al.
Publicado: (2021)

Age-related macular degeneration.
por: McConnell, V., et al.
Publicado: (2005)

Age-related macular degeneration
por: Querques, Giuseppe, et al.
Publicado: (2011)

Age-related macular degeneration
por: Mathenge, Wanjiku
Publicado: (2014)

Advances in the management of macular degeneration
por: Singer, Michael
Publicado: (2014)

Age-related macular degeneration: experimental and emerging treatments
por: Hubschman, Jean Pierre, et al.
Publicado: (2009)

Rescue effects of intravitreal aflibercept in the treatment of neovascular age-related macular degeneration
por: Hsia, Ning-Yi, et al.
Publicado: (2015)

LAMELLAR MACULAR HOLES IN THE PRESENCE OF AGE-RELATED MACULAR DEGENERATION
por: Francone, Anibal, et al.
Publicado: (2020)

Role of ranibizumab in management of macular degeneration
por: Singh, Rishi P, et al.
Publicado: (2007)

Pharmacogenetics and Age-Related Macular Degeneration
por: Schwartz, Stephen G., et al.
Publicado: (2011)

Prevention of age-related macular degeneration
por: Wong, Ian Yat Hin, et al.
Publicado: (2010)

Angiogenin in age-related macular degeneration
por: Skeie, Jessica M., et al.
Publicado: (2011)

Pharmacotherapy for Age-Related Macular Degeneration
por: Ahmadieh, Hamid
Publicado: (2008)

Perceptual learning in patients with macular degeneration
por: Plank, Tina, et al.
Publicado: (2014)

Rehabilitation Approaches in Macular Degeneration Patients
por: Maniglia, Marcello, et al.
Publicado: (2016)

Metabolomics and Age-Related Macular Degeneration
por: Brown, Connor N., et al.
Publicado: (2018)

Mapping the binocular scotoma in macular degeneration
por: Vullings, Cécile, et al.
Publicado: (2021)

Histology of neovascular myopic macular degeneration
por: Jonas, Shefali B., et al.
Publicado: (2021)

Choriocapillaris Changes in Myopic Macular Degeneration
por: Li, Jonathan, et al.
Publicado: (2022)

Nanotechnology for Age-Related Macular Degeneration
por: Yang, Bo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ko03vrkvc5p800qle4oqqbpmvt